Full-Time
Clinical Engineer 1
Zimmer Biomet Holdings
10,001+ employees
Develops joint replacement, robotics, smart implants
Compensation Overview
$60k - $80k/yr
Cherry Hills Village, CO, USA
Hybrid
 Biology & Biotech (1) |
|---|
Get referred to Zimmer Biomet Holdings
Find people who can refer or advise you
- Bachelor's degree in Mechanical Engineering, Biomedical Engineering, or related engineering/anatomy discipline.
- Minimum 1-3 years of clinical or medical device design experience.
- Mechanical aptitude and ability to visualize objects in 3D space.
- Process development and execution aptitude.
- Excellent problem solving, analytical, and organizational skills.
- Strong technical writing skills.
- Proficient with 3D design (parametric or surface modeling) software; SolidWorks and Materialise 3-matic preferred.
- Knowledge of basic engineering materials and manufacturing processes.
- Detail oriented and capable of handling multiple assignments at once.
- General knowledge of human anatomy and biomechanics.
- Materialise Mimics experience and familiarity with DICOM imaging preferred.
- Proficiency in Microsoft Office.
- Effective communication and presentation skills with ability to convey information and respond to questions from peers and colleagues.
- Ability to work in a team environment.
- Coordinate daily clinical production operations.
- Review medical imaging, including CT scans and x-rays.
- Virtually plan and review surgical procedures.
- Communicate with surgeons to gain approval of patient-specific surgical plans.
- Observe surgery (live, cadaver, or video) on lower extremity pathology.
- Interface with 3rd party suppliers, contractors, testing houses, etc.
- Create detailed reports and case documentation.
- Communicate with development and quality engineers for project-related issues.
- Perform quality checks to ensure patient-matched device designs meet released specifications.
- Develop, modify, and execute projects to improve patient specific processes.
- Initiates actions to resolve problems and improve process performance and reduce cost.
- Develop projects to improve PSI products and/or user experience.
- Support sales and user training as a PSI product expert.
- Support development team for new products.
- Performs other duties as assigned.
- Materialise Mimics experience and familiarity with DICOM imaging preferred.
- SolidWorks 3D CAD and Materialise 3-matic preferred.
Zimmer Biomet manufactures and markets musculoskeletal medical devices and instruments for joint replacement, surgical trauma, and sports medicine. Its products include joint implants, surgical tools, and smart implants, often supported by robotic-assisted surgery systems. The company develops, produces, and sells these devices and provides services such as medical education and training to healthcare professionals to support procedures and outcomes. Compared with competitors, Zimmer Biomet benefits from a long history (over 90 years), a global footprint, and a focus on integrated solutions that combine advanced implants with robotics technology and education partnerships. Its goal is to advance patient care by delivering reliable devices, technologies, and professional training that improve surgical outcomes and collaboration with healthcare providers.
Company Size
10,001+
Company Stage
IPO
Headquarters
Warsaw, Indiana
Founded
1927
Get referred to Zimmer Biomet Holdings
Find people who can refer or advise you
Simplify's Take
What believers are saying
- The $140M iovera° acquisition adds $24.2M non-opioid revenue and aligns with opioid legislation.
- Hiring 500 Bengaluru staff for AI robotics strengthens India as a global innovation capability hub.
- Securing $2.75B credit facilities ensures liquidity for acquisitions and sustains a 5.0-to-1.0 debt ratio.
What critics are saying
- Stryker’s Mako robot displaces Zimmer’s ROSA in knee arthroplasty, causing high capital sales loss soon.
- U.S. sales force transformation causes surgeon outreach gaps and stalls organic growth at 1–3% in 2026.
- Johnson & Johnson’s next-gen hip implants with AI navigation directly erode Zimmer’s $2.09B hip franchise growth.
What makes Zimmer Biomet Holdings unique
- Zimmer leads with 90+ years of musculoskeletal expertise and a comprehensive joint replacement portfolio.
- The company integrates ROSA robotics and AI-driven smart implants across its surgical solutions.
- Zimmer offers non-opioid pain relief via the newly acquired iovera° cryoneurolysis device.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Wellness Program
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 1%2 year growth
↑ 2%Zimmer Biomet names Chintan Desai president of Asia Pacific Region. Jul 14, 2026 WARSAW, Ind., July 14, 2026 /PRNewswire/ - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Chintan Desai has been named president of the company's Asia Pacific Region, effective immediately. "Chintan is a seasoned MedTech executive with nearly three decades of leadership experience at highly respected companies, along with deep expertise leading businesses across the Asia Pacific region," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "He knows this market, he knows how to lead, and he will be a strong addition to our team. I'm very much looking forward to the impact he'll make for our team, our customers and our Mission." Desai brings extensive proven leadership in the global medical technology industry, with deep experience across the Asia Pacific region. He joins Zimmer Biomet from Alcon, where he most recently served as vice president and general manager of International Growth and Export Markets and as a member of Alcon's International Leadership Team, based in Switzerland. Prior to that role, Desai was vice president for Alcon's Asia Pacific Surgical business based in Singapore, where he led the MedTech franchise across multiple markets in the region. Before joining Alcon, he spent more than 22 years at GE Healthcare in a variety of senior regional business leadership roles based in the United States, Singapore and Australia. His experience spans sales management, marketing, services, supply chain, finance and project management across medical devices, consumer health, digital solutions and capital equipment. Desai is a certified Chartered Accountant from India. He also completed the Executive Leadership Development Program at Kellogg School of Management at Northwestern University. He is an active volunteer and mentor for business schools and startups in the Asia Pacific region. Desai replaces Sang Yi, current group president of Asia Pacific, who will depart the company on Aug. 28 to ensure a smooth transition. Tornos added, "On behalf of the entire Zimmer Biomet team, I would like to thank Sang for his leadership and contributions over the past 13 years. He played an important role in advancing our strategy across Asia Pacific and helped drive meaningful growth for our company in a critical region of the world. We wish him all the best in his next chapter." About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. Zimmer Biomet Inc. seamlessly transform the patient experience through its innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Its legacy continues to come to life today through its progressive culture of evolution and innovation. For more information about its product portfolio, its operations in 25+ countries and sales in 100+ countries or about joining its team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet. Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission ("SEC"). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release. | Contacts: | / | | Media | Investors | | Troy Kirkpatrick | David DeMartino | | 614-284-1926 | 646-531-6115 | | [email protected] | [email protected] | | Kirsten Fallon | Zach Weiner | | 781-779-5561 | 908-591-6955 | | [email protected] | [email protected] | SOURCE Zimmer Biomet Holdings, Inc.
Indiana University and Zimmer Biomet launch research, workforce partnership. April 21, 2026 By dan spalding news now Warsaw. WARSAW - Indiana University and Warsaw-based Zimmer Biomet have entered into a new partnership designed to accelerate technologies that improve joint replacement, bone healing, and mobility. The agreement will result in collaboration on research and development, technical training and credentialing, as well as workforce development initiatives. "This is a significant moment for Indiana University," said IU President Pamela Witten during Monday's announcement. "It's exactly the kind of partnership that reflects who we are as a university. (0:27) More innovative, more engaged, and more determined than ever to move great ideas into things that have real-world impact," she said. It appears the agreement could serve as a direct boost to Warsw's massive collection of orthopedic firms beyond just Zimmer Biomet. IU's statement on Monday says the focus will be on meeting the evolving needs of Indiana's orthopedic sector. Zimmer Biomet President Victor Tornos also celebrated the announcement that further deepens the orthopedic leader's roots in Indiana. "So when you have a bold vision, you need bold partners. And that's what Indiana University has right here. A bold vision, with bold partners, with great students," Tornos said. "Today is a very exciting day, not just for the university, for the state of Indiana, but for the world," he added. A central component of the collaboration is Zimmer Biomet's support and engagement in the Indiana Musculoskeletal Health Partnership for the Advancement of Care & Treatment, or IMPACT, an IU-led statewide consortium shaping Indiana's leadership as a global hub for orthopedic innovation, the news release said. The consortium, named a finalist in the National Science Foundation's Regional Innovation Engines competition, brings together more than 100 partners across academia, industry and government to bridge the gap between patients' unmet medical needs and the technologies that can solve them, including smarter implants and wearable diagnostics. Zimmer Biomet will also engage with faculty and students from the IU Kelley School of Business on applied, interdisciplinary projects focused on practical challenges in the orthopedic sector, including supply chain optimization, operational efficiency and innovation strategy, the news release said. The IU portion of the partnership will be led by the IU Launch Accelerator for Biosciences, known as IU LAB. "IU LAB exists to turn Indiana University's research strengths into solutions that matter in the real world," IU LAB President and CEO David Rosenberg said. "The partnership with Zimmer Biomet does exactly that: embedding industry insight, shared infrastructure and market urgency directly into its research and talent pipeline. "Together with Zimmer Biomet, we are shortening the distance between discovery and deployment while cementing Indiana as the world's leader in orthopedic innovation," Rosenberg said.
Zimmer Biomet has appointed Dr Jonathan Vigdorchik as Chief Science, Technology and Medical Affairs Officer, effective 14 April. He will oversee the company's global technology portfolio, including AI, robotics, smart implants and data, whilst managing medical education strategy and the Global Advisory Board. Dr Vigdorchik previously served as Zimmer Biomet's Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants. He is a board-certified orthopaedic surgeon at Hospital for Special Surgery in New York and Associate Professor of Orthopaedic Surgery at Weill Cornell Medical College. The appointment reflects Zimmer Biomet's focus on advancing its robotic and enabling technologies, with Dr Vigdorchik reporting to Chairman, President and CEO Ivan Tornos. He will help accelerate the company's innovation roadmap and strengthen clinical engagement.
Zimmer Biomet appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer. PR Newswire Today at 4:30am PDT Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacity WARSAW, Ind., April 7, 2026 /PRNewswire/ - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14. In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of the company's global end-to-end technology portfolio, including AI, robotics, smart implants and data. He will also oversee Zimmer Biomet's Medical Education strategy and Global Advisory Board, helping further strengthen Zimmer Biomet's clinical engagement, innovation roadmap and external scientific leadership. Dr. Vigdorchik will report to Ivan Tornos, Chairman, President and Chief Executive Officer. "Dr. Vigdorchik is a world-class orthopedic surgeon, and he brings exactly the kind of bold, future-focused leadership we need as we continue to shape the next era of musculoskeletal care," said Tornos. "He understands how to translate clinical insight into meaningful innovation, and his leadership will help us move faster, think bigger and continue advancing our broad suite of robotic and enabling technologies. I'm confident he will play a critical role in accelerating our portfolio strategy and further differentiating Zimmer Biomet in the market." Dr. Vigdorchik previously served as Zimmer Biomet's Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants. He is a board-certified, fellowship-trained orthopedic surgeon at Hospital for Special Surgery (HSS) in New York City, specializing in hip and knee replacement surgery. Dr. Vigdorchik held several prominent academic and clinical leadership positions, including serving as Division Chief for national/international reputation and academic promotion on the Adult Reconstruction and Joint Replacement service at HSS and Director of Bone Implant Longevity Research at HSS's Griffin Research Accelerator. In addition, he is currently an Associate Professor of Orthopaedic Surgery at Weill Cornell Medical College. He is active in professional societies including The Hip Society, The Knee Society, the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Hip and Knee Surgeons (AAHKS), where he served as the Education and Communications Council Chair and earlier served as Program Chair for the 2024 AAHKS Annual Meeting. "As a surgeon and innovator, I believe we are at an inflection point where AI, data, and advanced technology will fundamentally redefine the future of orthopedics," said Dr. Vigdorchik. "I've dedicated my career to focus on preventing complications and achieving consistently better outcomes for patients. With strength across its product portfolio, a differentiated suite of robotic and enabling technologies, and a pathway toward fully autonomous robotic technology in orthopedics, Zimmer Biomet is poised to continue pushing the industry forward. I'm excited to join the talented team in this expanded role to help advance that vision and accelerate innovation for surgeons and patients around the world." Dr. Vigdorchik earned his medical degree from the University of Missouri - Columbia School of Medicine, completed his orthopaedic surgery residency at the Detroit Medical Center / Providence Hospital, and received fellowship training in Adult Reconstruction and Joint Replacement at HSS. He also completed an international traveling fellowship in hip preservation surgery with training at centers in Switzerland, Boston Children's Hospital, and Washington University in St. Louis. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release. | Contacts: Media Troy Kirkpatrick 614-284-1926 [email protected] Kirsten Fallon 781-779-5561 [email protected] | Investors David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] | SOURCE Zimmer Biomet Holdings, Inc. This is a paid placement. For further inquiries, please contact PR Newswire directly.
Zimmer Biomet wins three awards at Healthcare Asia Medtech Awards 2026. March 27, 2026 Awards Recognize Innovations in Infection Measures, AI-Driven Recovery and Surgeon Engagement across Asia Pacific. SINGAPORE, March 27, 2026 /PRNewswire/ - Zimmer Biomet (NYSE and SIX: ZBH), a global medical technology leader, today announced it received three awards at the Healthcare Asia Medtech Awards 2026, recognizing the company's innovations across orthopedic product development, digital health and surgeon engagement. * Orthopedic Product Innovation Award for its new iodine-treated hip implant; * Digital Innovation of the Year in Australia for its WalkAI knee replacement recovery tracking platform; and * Marketing & Communications Initiative of the Year in Thailand for its You'll Be Back awareness campaign featuring Arnold Schwarzenegger as the company's Chief Movement Officer. "These awards reflect the strength of Zimmer Biomet's innovation and the relevance of our solutions across Asia Pacific," said Sang Yi, Group President, Asia Pacific. "From addressing infection risk with advanced implant technologies, to enabling more proactive, data-driven recoveries and strengthening how we engage surgeons, we are focused on solving the most meaningful health care challenges and improving outcomes for patients across the region." Advancing Infection Measures in Orthopedics Zimmer Biomet received the Orthopedic Product Innovation Award for its implants treated with iodine technology, the iTaperloc Complete and iG7 Hip System. These implants are designed to inhibit bacterial adhesion[1] [,] [2] and reduce the risk of periprosthetic joint infection, a serious complication affecting approximately 1%-2% of primary procedures.[3] Iodine, a biocompatible nutrient, helps prevent biofilm formation without contributing to antibiotic resistance.[4] [,] [5] The technology has received regulatory recognition globally, including approval from Japan's Ministry of Health, Labour and Welfare in September 2025 and Breakthrough Device Designation from the U.S. Food and Drug Administration in October 2025. Advancing Recovery Through AI Zimmer Biomet's WalkAI platform received the Digital Innovation of the Year - Australia award. The application uses artificial intelligence to analyze real-world mobility data and predict a patient's 90-day gait speed following total knee replacement surgery. By identifying deviations in recovery between days 15 and 40 post-surgery, a typically "lower-touch" period in care, WalkAI is designed to flag patients who may not be recovering as expected and enable earlier clinical intervention. This added visibility allows surgeons to prioritize patients who may require closer monitoring or adjustments to rehabilitation, helping reduce the risk of complications. The platform is currently used by more than 180 surgeons across Australia and New Zealand to support over 20,000 knee replacement patients, demonstrating strong clinical adoption and scalability in practice. Raising Awareness of Movement and Treatment Options The Marketing & Communications Initiative of the Year - Thailand award recognized the "You'll Be Back" campaign, which builds on Zimmer Biomet's partnership with Arnold Schwarzenegger as the company's Chief Movement Officer. Launched at the Royal College of Orthopaedic Surgeons of Thailand Annual Conference, the campaign was adapted specifically for a highly regulated market through close collaboration across corporate communications, marketing, legal and compliance teams. Rather than focusing on product promotion, the initiative centered on the importance of movement and aimed to raise awareness of available treatment options for people living with pain. The message resonated strongly by shifting conversations beyond products toward recovery, longevity and quality of life. The campaign significantly increased engagement, with booth interactions tripling year over year and strong resonance among surgeons. The Healthcare Asia Medtech Awards recognize leading companies and innovations across the region, highlighting advancements in medical devices, digital health and patient care solutions. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. Siam News Network Pte. Ltd. seamlessly transform the patient experience through its innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Its legacy continues to come to life today through its progressive culture of evolution and innovation. Zimmer Biomet: | Media | Investors | | Addie Elicano | David DeMartino | | 65-8220-8766 | 646-531-6115 | | [email protected] | [email protected] | | Troy Kirkpatrick | Zach Weiner | | 614-284-1926 | 908-591-6955 | | [email protected] | [email protected] | | 1 D. Inoue et al. (2017), Inhibition of biofilm formation on iodine-supported titanium implants, Int Orthop (SICOT) 41: 1093-1099 | | 2 D. Inoue et al. (2019), Iodine-supported titanium implants have good antimicrobial attachment effects, J Orthop Sci 24: 548-551 | | 3 Izakovicova, P., Borens, O., & Trampuz, A. (2019). Periprosthetic joint infection: current concepts and outlook. EFORT open reviews, 4(7), 482-494. https://doi.org/10.1302/2058-5241.4.180092 | | 4 T. Shirai et al. (2013), Antibacterial iodine-supported titanium implants, Acta Biomater 7(4): 1928-1933 | | 5 T. Shirai et al. (2023), Iodine-supported implants in prevention and treatment of surgical site infections for compromised hosts: a prospective study, J Orthop Surg Res 18(1): 388 | The information provided in this article was created by Cision PR Newswire, its news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Siam News Network.